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Summary
The CD2 antigen is the target for an "alternative" T cell activation pathway. Numerous studies
have demonstrated that pairs of monoclonal antibodies (mAbs) directed toward two different
epitopes are required for activation of T cell receptor (TCR)-c1/0+ T cells via CD2 . We have
now explored the activation ofhuman TCR-y/b+ T cell clones by a panel of anti-CD2 mAbs
directed against the sheep erythrocyte-binding (T11.1) epitope of CD2. Seven of seven -Y/b+
clones expressing different molecular forms of the TCR-y/b responded to stimulation by a single
anti-CD2 mAb (OKT11, 9E8, BW0110, M-T910) with IL-2 secretion and/or proliferation .
Immobilization of anti-CD2 mAbs in microculture plates was essential for activation of 'r/b+
clones, which occurred in the absence offeeder cells . In addition to interleukin 2 (1172) production
and proliferation, anti-CD2 mAbs also triggered cytotoxic effector activity in 'r/b + clones as
measured against FcR+ P815 target cells . In contrast to y/b+ clones (but in line with established
data), none of five CD4+ or CD8+ TCR-a/(3+ clones were activated by any of the tested
individual anti-CD2mAbs. Taken together, our results reveal a striking difference between cloned
y/b+ and a/a+ T cells in that y/b+ T cells are selectively activated by a single anti-CD2 (T11.1)
mAb, without need for the simultaneous signal of a second anti-CD2 mAb directed against
another (T11.2 or T11.3) CD2 epitope.
T
cells are activated by the antigen-specific TCR/CD3 mo-
lecular complex following interaction with foreign an-
tigenic peptides in association with selfMHC proteins. In
addition, T cells can be activated via an "alternative" pathway
through the CD2 cell surface antigen (1) . CD2 is a 50-55-
kD single-chain glycoprotein expressed on the vast majority
of peripheral bloodT cells and thymocytes (2, 3) . Three epi-
topes have been defined on theCD2 molecule, of which T11.1
and T11.2 are expressed on resting T cells, while T11.3 (now
designated C132R) is a conformational epitope that only ap-
pears after activation (1) . Soluble mAbs directed against TILL
the sheep erythrocyte-binding epitope ofCD2, inhibit cer-
tain T cell functions such as 11,2 production, IL-2-depen-
dent proliferation, and cytotoxic effector activity (4-8) . Pairs
of mAbs directed against the T11.2 and T11.3 epitopes in
combination activate resting T cells (1, 9, 10) . One of the
two anti-CD2 mAbs required for T cell activation may be
replaced by the natural ligand for CD2, LFA-3, by sheep
erythrocytes, or by PMA (11-13) . Moreover, cytolytic activity
can be triggered in CD2+CD3-TCR - NK cells by a mito-
genic combination of two anti-CD2 mAbs, or by a single
anti-CD2 mAb (5, 8, 14) . In the latter case, however, CD2
must be cross-linked with CD16, the low affinity Fcy receptor
(14) . Thus, it is obvious that activation of TCR-a//3+ T
cells and TCR - NK cells via CD2 requires two signals.
A minor fraction of peripheral blood T cells (1-10%) ex-
press aTCRy/b heterodimer noncovalently associated with
theCD3 complex (15) . The biological significance, including
the antigen specificity of y/b+ T cells, is still a matter of
debate (15, 16) . A striking feature of -y/b+ T cells is their
frequent reactivity towards mycobacterial antigens (17-20) .
Activation requirements of -y/b+ T cells have not been thor-
oughly investigated so far. Established y/b+ clones can be
stimulated to secrete IL-2 and other cytokines (21), but freshly
isolated -y/b+ T cells produce less 11,2 upon PMA stimula-
tion than do a/a+ T cells (22) .
In the present study we have analyzed the "alternative"
CD2 activation pathway in cloned -y/b+ T cells. We found
that single anti-CD2 (T11.1) mAbs strongly triggered the
activation of seven of seven TCR-7/6+ clones, while none
out of five TCRa/a+ clones were stimulated under these
conditions. These results reveal a striking difference between
cloned y/b+ and a/a+ T cells regarding the CD2-depen-
dent activation pathway.
Materials and Methods
Establishment ofIL2-dependent y/d+ and a/,8' T Cell Clones.
PBMC from normal donors were isolated by Ficoll-Hypaque den-
sity gradient centrifugation. After depletion ofplastic-adherent cells,
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cedure using neuraminidase-treated sheepE. y/6' T cells were en-
riched from E-rosetting T cells as described (22) . Briefly, T cells
were incubatedwith supernatants ofOKT4 (anti-CD4) andOKT8
(anti-CD8) hybridomas (both from American Type Culture Col-
lection, Rockville, MD). After being washed, the cells were in-
cubated with nontoxic rabbit complement (Cedarlane Laborato-
ries, Hornby, Ontario) for 1 h at 37°C . Dead cells were removed
by Ficoll-Hypaque density gradient centrifugation . Viable cells were
cultured at 0.3 cells per well in 96-well round-bottomed culture
plates (Nunc, Roskilde, Denmark) in the presence of 105 irradi-
ated PBMC feeder cells and 0.5 hg/ml PHA-P (Wellcome, Burg-
wedel, FRG) . The culture medium was RPMI 1640 (Biochrom
KG, Berlin, FRG) supplemented with 10% heat-inactivated FCS
(batch4MO2 ; Biochrom KG), antibiotics, 2mM L-glutamine, and
10 mM Hepes. After 2 d, rIL2 (EuroCetus, Amsterdam, The
Netherlands) wasadded at 2 ng/ml . Growing clones were expanded
in 24-well culture plates (Greiner, Ntirtingen, FRG) in rIIL2-sup-
plemented medium. Every 10-14 d, the clones were restimulated
with feeder cells (mixture of 106 irradiated PBMC per milliliter
plus 105 irradiated EBVtransformedLCL per milliliter) and PHA-P
(0.5 Pg/ml). In some cases, y/6+ clones were established after iso-
lation of 7A5' (Vy9+) T cells on a cell sorter (FACStar Plus ;
Becton Dickinson & Co ., Mountain View, CA) . a/o' T cell
clones were obtained by culturing E-rosette separated T cells at
0.3 cells per well under the above described culture conditions.
Phenotypic Characterization ofTCell Clones.
￿
TheantiTCRmAbs
used for the phenotypicTCRcharacterization ofestablished clones
are listed in Table 1. Commercial mAbs TCR61 and 6-TCS1 (T
Cell Sciences, Cambridge, MA) were used as FITC-conjugates,
whereas indirect staining procedures were applied in conjunction
with noncommercial mAbs . In this case, FITC-conjugated F(ab') z
goat anti-mouse IgG (Tago, Burlingame, CA)wasused as a second-
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step reagent . mAbs A13 (23) and BB3 (24) were kindly provided
by Dr. L. Moretta (Istituto Nationale, Genoa, Italy), and mAbs
TiyA (25) andTiV62 (26) were the generous gifts of Drs .T Her-
cend and F . Triebel (Institut Gustave Roussy, Villejuif, France) .
mAb7A5 '(IgGl)was made in our laboratory. It recognizes aVy9-
encoded TCR determinant (26a) . Anti-CD3 mAb OKT3 was
generously provided by Cilag GmbH (Sulzbach, FRG) . FITC- or
PE-conjugated anti-CD4 (Leu3) andanti-CD8 (Leu2a)mAbs were
purchased from Becton Dickinson & Co. After being stained,
samples were resuspended in 1% paraformaldehyde . All analyses
were measured on a FACScan cytofluometer (Becton Dickinson
& Co.) .
Anti-CD2 mAbs.
￿
Anti-CD2 mAbs used in this study are listed
in Table1. mAb 9E8 was obtained in our laboratory from a fusion
of spleen cells from a female Balb/c mouse immunized with a
CD2 `y/S* human T cell clone. 9E8 blocks rosette formation be-
tweenhumanT cells and sheep E, and identifies by Western blot
analysis a single band of-50kD mol mass on resting T cells and
established T cell clones (our unpublished results) . Basedon these
criteria,mAb 9E8 is classified as anti-CD2 . Like 9E8, all other anti-
CD2 mAbs listed in Table 1 strongly react with resting T cells
andblockE rosette formation . Therefore, they are classified as anti-
CD2 (anti-T11 .1) and notanti-CD2R mAbs (27) . Hybridoma cells
producing OKT11mAb (IgGl) were obtained fromATCC . IOT11
and IOT11a were from Dianova (Hamburg, FRG) . mAb MT910
(28) waskindly donated by Dr. E.P. Rieber (University ofMunich,
FRG), and mAbs BW0110, BMA030 (anti-CD3), and BMA031
were generously provided by Drs. K.H . Enssle and R. Kurrle
(Behringwerke, Marburg, FRG) . mAbs OKT11 (ATCC), 9E8,
OKT4 (ATCC), and 7A5 were purified from hybridoma culture
supernatants on protein Gcolumns (Pharmacia, Uppsala, Sweden).
Cell Cultures.
￿
Cloned y/6+ (and a/fl') T cells were cultured
in the presence ofimmobilized or cross-linked anti-CD2 mAb, and
Table 1 . mAbs Used in this Study
Antibody Specificity Ig subclass Source (reference)
OKT3 CD3 IgG2a Cilag (Sulzbach, FRG)
BMA030 CD3 IgG2a Dr . Kurrle (Behringwerke)
BMA031 TCR-cx/(3 IgG2b Dr . Kurrle (42)
TCR6-1 TCR CS IgG1 T Cell Sciences (43, 44)
7A5 TCR Vy9 IgG1 This laboratory
TiyA TCR Vy9 IgG2a Dr . Hercend/Dr . Triebel (25)
TiV62 TCR V62 IgG1 Dr . Hercend (26)
BB3 TCR V62 IgGl Dr . L. Moretta (24, 45)
A13 TCR V61 IgG1 Dr . L. Moretta (23, 26)
6TCS-1 TCR V61J61,
V61-J62 IgGl T Cell Sciences (45, 46)
OKT1l CD2 IgGl ATCC
9E8 CD2 IgGl This laboratory
BWO110 CD2 IgG2b Dr . Enssle (Behringwerke)
M-T910 CD2 IgG1 Dr . Rieber (28)
IOTI l CD2 IgG1 Dianova (Hamburg, FRG)
IOT11a CD2 IgG2a (rat) Dianova
OKT4 CD4 IgG2b ATCCProliferation and 11,2 production were measured as parameters of
cellular activation. To immobilize mAbs in culture plates, wells
of 96-well, round-bottomed culture plates (Nunc) were coated for
18 h with 1 ug purified mAb in PBS per well. The plates were
washed twice with PBS, and clone cells were added at 3-5 x 104
cells per well in a total volume of 200 Id in RPMI 1640/10% FCS
without exogenous IL2. Alternatively, T cell clones were incubated
for 30 min on ice with the respective mAb, washed twice, and
added at 3-5 x 104 cells per well to U-bottomed microculture
plates previously coated with 1 Rg per well of goat anti-mouse
IgG (Tago) . All cultures were incubated at 37°C in a humidified
atmosphere of5% COZ in air. After 18-24 h, 75 P,l of superna-
tant was removed from each well and transferred to a 96-well flat-
bottomed microculture plate for determination of11,2 content. After
an additional 12-24 h, 1 IACi ['H]TdR (specific activity 6.7 Ci/
mmol) per well was added to the remaining cells, and incubation
was continued for another 6 h . Afterwards, the cultures were har-
vested and prepared for counting of fi emission in a Packard liquid
scintillation counter . Results are expressed as mean cpm of tripli-
cate cultures . SD were always <15%.
Determination of 11,2 Production. IL2 produced by mAb-
stimulated T cell clones was detected in a colorimetric assay on
IL-2-dependent murine CTLL cells as described (29) . Briefly, 15,000
CTLL cells per well were added to flat-bottomed culture plates
containing supernatants of T cell clones . After incubation for 24
h at 37°C/5% CO Z , the tetrazolium salt MTT (Sigma, Deisen-
hofen, FRG) was added at 250 fcg/ml, and incubation was con-
tinued for another 4 h . Formazan crystals were solubilized in 10%
SDS/1% HCl, andOD at 570 nm were read on an ELISA reader
with the reference wave length set at 690 nm . This assay is highly
specific for IL2 ; the CTLL clone used does not respond to human
rILl, rIL3, or rl1r4 (29) .
Cytotoxicity Assay .
￿
FcR' murine P815 mastocytoma cells were
used in a standard 4-h "Cr-release assay to evaluate the cytotoxic
effector activity of cloned T cells in the absence or presence of
different mAbs. Percentage specific lysis was calculated as follows :
Percent specific lysis = 100 x [(cpmaperimentai - cpmsponunrnus)/
(cprnmiximal - cprrrsponuneous)] "
Results
Immobilized Single Anti-CD2 mAbs Stimulates Proliferation
ofy/b+ Clones. We have investigated possible stimulatory
effects of anti-CD2 mAbs on cloned y/S' T cells. To this
end, clone cells were added to mAb-coated culture plates,
and [ 3H]TdR incorporation was determined after 36 h o£
culture. As shown in Fig. 1, y/S' clones strongly prolifer-
ated in response to individual immobilized anti-CD2 mAbs.
All stimulatory anti-CD2 mAbs depicted in Fig. 1 were
directed against the T11.1 epitope. It should be stressed, how-
ever, that stimulation of -y/S+ T cell clones could not be
achieved with every anti-CD2 mAb. Among the anti-CD2
mAbs tested (see Table 1), OKT11 (ATCC), 9E8, M-T910,
and BWO110 were stimulatory, whereas ICT11 and IOT11a
were not (not shown) . There was no obvious correlation be-
tween the stimulatory capacity of a given anti-CD2 mAb
and its IgG subclass. Thus, stimulatory anti-CD2 mAbs were
either IgG1 (OKT11 [ATCC], 9138, M-T910) or IgG2b
(BW0110), and nonstimulatory mAbs were either IgG1
(IOT11) or IgG2a (IOT11a) . Note that y/S+ clones ex-
pressing different molecular forms of theTCRy/b as deduced
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(A) D768/5
(B) D768/6
(C) A92DN3
(D) D768/4
(E) B54
Figure 1 .
￿
Proliferative response ofcloned y/S+ T cells to immobilized
single anti-CD2 mAbs. 5 x 104 clone cells expressing different molec-
ular forms of the TCR-y/S (see Table 2) were cultured in triplicate in
microculture plates previously coated with 1 jig per well of the indicated
purified mAb . [ 3H]TdR incorporation was determined after 36 h. The
proliferative response to rIL2 (3 ng/ml) was used as a positive control .
The following mAbs were used : anti-CD2 : OKT11 (ATCC), 9138, BW
(BWO110), MT (MT910); antiTCR y/b : 7A5 (antiVy9) ; anti-CD3 :
OKT3 ; anti-CD4: OKT4 .
by reactivity with antiVy and antiV6 mAbs (see Table 2
for phenotypic analysis) were all activated by stimulatory anti-
CD2 mAbs . In contrast, activation by immobilized antiVy9
mAb 7A5 was restricted to Vy9-expressing clones (D768/6,
A92DN3, D768/4, B54; see Fig. 1) . As a control, immobi-
lized anti-CD4 mAb OKT4 did not stimulate CD4 - y/6'
clones .
A second protocol was equally efficient in eliciting CD2-
dependent activation of -y/b+ clones. Here, clone cells were
first incubated with anti-CD2 mAb, then washed, and cul-tured in microculture plates previously coated or not with
goat anti-mouse Ig. Under these conditions, Vy9-expressing
D768/6 clone cells strongly proliferated (Fig . 2) . No prolifer-
ative response was observed, however, when anti-CD2-la-
beled -y/S+ clones were cultured in microculture plates not
coated with anti-mouse Ig, indicating that cross-linking of
cell surface CD2 molecules was essential to trigger prolifera-
tion (Fig . 2) .
The stimulatory effect ofindividual immobilized anti-CD2
mAbs was strikingly specific for -y/b+ cells. As illustrated
in Fig . 3, none of five well-characterized (CD4+ or CD8 + )
TCR a//3+ clones proliferated in response to immobilized
single anti-CD2 mAbs OKT11 (ATCC) or 9E8, while all
of them were activated by plastic-bound anti-CD3 (OKT3)
or antiTCR-a/(3 (BMA031) mAbs .
Immobilized Single Anti-CD2 mAbs Stimulate IL2 Produc-
tion in y/8+ Clones. The above data showed that triggering
by a single immobilized or cross-linked anti-CD2 mAb in-
duced autocrine proliferation of -y/S+ but not ca/o+ T cell
clones. To investigate whether this proliferative response was
IL2 dependent, we measured IL2 in cell-free culture super-
natants of anti-CD2-stimulated y/S+ clones . As shown in
Fig . 4, IL2 production was induced in all four analyzed
,y/b+ clones by at least two of the tested anti-CD2 mAbs.
However, not all anti-CD2 mAbs that stimulated prolifera-
tion of a given -y/b+ clone (Fig. 1) also triggered measur-
able IM production. Of interest, certain anti-CD2 mAbs
were effective on some but not other -y/b+ clones. It is thus
evident that the anti-CD2-triggered autocrine proliferation
of y/S+ clones is not necessarily dependent on the secretion
of detectable amounts of 11,2 into the culture medium.
A Single Anti-CD2 mAb Triggers Cytotoxic Ejector Func-
tion in TIP but not a/#+ Clones. Next we asked whether
anti-CD2 mAbs could also trigger cytotoxic effector func-
TCRS-1
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Ti,yA 7A5 BB3 TiV62 6TCS-1 A13
tion in cloned y/S+ T cells . Lysis of FcR+ murine P815
target cells is a well-established system to monitor anti-
CD3/TCR mAb-triggered activation ofCTL . As shown in
Fig . 5 A, -y/b+ clone D768/3 expressing a Vy9/V62 TCR
did not kill P815 target cells in the absence of added anti-
body. Anti-CD3 (OKT3, BMA030), antiTCR Vy9 (7A5),
and anti-CD2 (OKT11 [ATCC]) mAbs all triggered cyto-
toxic activity, whereas antiTCR-a/p mAb BMA031 was
without effect . A second y/b+ clone expressing a different
TCR phenotype (V-y9 - /VSl+) displayed some spontaneous
cytotoxic activity against P815 target cells (Fig . 5 B) . Again,
the cytotoxic activity was increased by anti-CD2 (OKT11
Figure 2 .
￿
Cross-linking is required for anti-CD2-mediated stimulation
of .y/S+ clone cells . Aliquots of.y/S+ clone D768/6 were incubated for
20 min on ice with the indicated mAbs. After being washed twice, clone
cells (5 x 10 4 per well) were cultured in triplicate in microculture plates
that had been previously coated (®) or not (/) with goat anti-mouse
IgG. [ 3H]TdR incorporation was measured- after 36 h .
Table 2 .
Clone
Phenotypic
CD2
Characterization
CD4
of T
CD8
Cell Clones
BMA031
TCR-y/S
D768/3 +
D768/4 +
B54 + i
A36DN33 +
D768/5 +
A92DN3 +
D768/6 +
TCR-cx/a+ :
A37/2 + + - +
D798/11 + + - +
D798/18 + + - +
D894/25 + + - +
D904/4 + - + +cprn x 1000
(A) D894/26
(B) A37/2
(C) D904/4
(D) D798/11
(E) D798/18
Figure 3 .
￿
Cloned a/g+ T cells do not proliferate in response to im-
mobilized anti-CD2 mAb . Four different CD4' clones (A, B, D, E) and
one CD8+ clone (C) were analyzed . Experimental system as in Fig. 1.
[ATCC]) and anti-CD3 (OKT3, BMA030) but not bymAbs
7A5 or BMA031 . Triggering of cytotoxic effector function
by anti-CD2 mAb OKT11 was not observed with a TCR
cx/a+ clone (Fig. 5 C) . As expected, however, this clone was
responsive to signaling by anti-CD3 or antiTCR-ot//3 mAbs.
Discussion
Our experiments revealed a striking difference between
cloned TCR-7/6+ and MR-a/0i+ T cells with respect to
stimulation via the alternative CD2 activation pathway. It
is well established that the CD2-dependent activation of a/a+ T cells requires two signals provided by two mAbs
directed against different epitopes of CD2 (1, 9, 10) . One
of the two signals can be replaced byLFA3 (the natural ligand
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600
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soo
200
100
OD x 10-3
600
400-
300-
200-
100-
0
￿
- - R.-
none OKT11 BE8
￿
BW
￿
MT
￿
7A8 OKT3 OKT4 rIL2
0
none OKT11 9E8
￿
BW
￿
MT
￿
7AG OKT3 OKT4 rIL2
(A) D768/4
(B) A36DN33
(C) D768/6
(D) D768/5
Figure 4.
￿
11,2 production by y/6+ clones. Four 7/8+ clones expressing
different molecular forms of the TCR--(/b (see Table 2) were cultured,in
mAb-coated plates as described in the legend to Fig . 1 . After 24 h, super-
natants were transferred to flat-bottomed microculture plates, and 11,2-de-
pendent CTLL cells were added . After additional incubation for 24 h,
viability ofCTLL cells was determined in a colorimetricMTT assay (29) .
Results are given as mean OD x 10-3 of triplicate cultures. rII.2 (3
ng/ml) was added to CTLL cells as a positivecontrol . BW, BWO110 ; MT,
MT910 .
for CD2), sheep E, or PMA (11-13) . We now report that
stimulation with a single anti-CD2 mAb in the absence of
feeder cells is sufficient to triggerIL2 production, prolifera-
tion, and cytotoxic effector activity in y/b+ clones ex-
pressing distinct molecular forms of the TCR-y/&
Activation requirements of y/b+ T cells have not been
thoroughly studied . A proliferative response of freshly iso-
lated resting -y/S+ cells can be initiated by PHA, anti-CD3
mAb, or alloantigenic stimulation (22, 30) . AfterPHA stim-
ulation, purified -y/S+ cells produce less 11,2 than a/a+
cells, and proliferation of y/S+ cells can be triggered in the
absence of detectable amounts of secreted IL-2 (22) . In lineFigure 5 .
￿
Soluble anti-CD2 rnAb triggers cytotoxic effector function
in y/6+ clones . Cloned y/S+ (A, B) or a/(3+ (C) cells were tested
against P815 target cells in the absence or presence of 1 leg/ml of the indi-
cated rnAb. E/T ratio was 5 :1 .
with these results, we found that the anti-CD2 triggered
proliferation of cloned y/6+ T cells was not necessarily as-
sociated with the secretion of measurable 11,2, although some
anti-CD2 mAbs induced strong IL2 production . It remains
to be established whether growth factor(s) other than IL2
(e.g., IL4) contribute to the autocrine proliferation of y/6+
clones in response to anti-CD2 signaling .
As shown here, established y/6+ clones are selectively ac-
tivated by immobilized or cross-linked single anti-CD2 mAbs .
The responsiveness of a given y/6+ clone to anti-CD2 sig-
naling does not depend on the experimental protocol used
to establish the clone . Although most clones were obtained
from purified CD4-CD8 - cells after isolation of E-rosetting
T cells, several y/6+ clones were established after sorting
of 7A5+ (Vy9+) T cells from unseparated PBMC . These
clones were equally susceptible to anti-CD2 signaling (not
shown) . The present results raise the important issue of
whether this selective activation pathway is also operational
in resting polyclonal y/6+ T cells . A prerequisite to address
this question is the ability to isolate sufficiently pure y/6+
T cells by negative selection, so as not to interfere with
CD3/TCR triggering during positive selection (e.g., cell
sorting involving antiTCR mAbs) . Experiments to study
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the CD2-dependent activation pathway of primary y/6+ T
cells are now in progress.
Given that single anti-CD2mAbs directed against the sheep
E binding epitope stimulate y/6+ but not a/J3+ clone
proliferation, one might expect similar effects utilizing sheep
E instead of anti-CD2 mAb. However, under various ex-
perimental conditions, we never did observe activation (defined
as cellular proliferation or IL-2 production) of cloned y/6+
T cells in the presence of sheep E only. It is thus obvious
that cross-linking of the T11.1 epitope by a single anti-CD2
mAb provides a stronger activation signal to cloned y/6+
T cells than binding of sheep E to cell surface T11.1 . In this
context it is of interest that cross-linking of an individual
anti-CD2 mAb induces Cat+ mobilization also in a/o' T
cells, without directly stimulating T cell proliferation (31) .
TCRindependent "alternative" activation pathways have
been previously studied with cloned y/6+ T cells . Interest-
ingly enough, activation viaCD28 (32) appears to be deficient
in y/6+ cells, due to the lack of CD28 expression on many
y/6+ T cells (33) . With regard to CD2 activation, Ferrini
et al. (33) reported on the activation of y/6+ clones by an
appropriate combination of two different anti-CD2 mAbs .
However, data reported from other groups support our present
results that y/6+, but not a/R+ T cells, can be activated
by single anti-CD2 mAbs . Thus, Goedegebuure et al . (34)
demonstrated that the lytic machinery can be triggered in
y/6+ but not a/a+ T cell clones by bispecific heterocon-
jugates containing a single anti-CD2 (TIM) mAb cross-linked
to anti-DNP. Recently, Pawelec et al . reported that 2 of 13
anti-CD2 mAbs from the 4th International Leukocyte Typing
Workshop (35) singly stimulated autocrine y/6+ T cell
clone proliferation (36) . In contrast to our results, however,
the presence ofEBVtransformedLCL feeder cells was abso-
lutely required in their system . Thus, no y/6+ clone acti-
vation was observed with immobilized individual anti-CD2
mAbs in the absence of feeder cells (36) . The apparent dis-
crepancy to our present results is most likely due to the usage
of different anti-CD2 mAbs in the two studies . As a matter
of fact, none of the four stimulatory anti-CD2 mAbs used
in our experiments (Table 1) was included in the study of
Pawelec et al . (36) . It is obvious from both studies that not
all anti-CD2 (T11.1) mAbs individually activate y/6+ T cell
clones, be it in the absence (this study) or presence (36) of
feeder cells. It is presently unclear why certain anti-CD2mAbs
are stimulatory while others are not . The Ig isotype does
not appear to be critical because IgG1 anti-CD2 included both
stimulatory (OKT11 [an IgG1 reagent from AMC], 9E8,
M-T910) and nonstimulatory (IOT11, OKT11 [anIgG2A re-
agent from Ortho Diagnostics, Raritan, NJ] ; not shown)
mAbs . It will be important to precisely characterize the
stimulatorymAbs with respect to the recognized epitope (37) .
In this context, it is of interest that anti-CD2 (T11.1) mAbs
can be classified into two subgroups (T11.1A, T11.1B ; refer-
ence 38) . While both T11.1A and T11.1B mAbs block E ro-
sette formation and inhibit binding of LFA-3, T11.1A anti-
bodies can replace the triggering signal provided by LFA3,
whereas T11.1B antibodies exert suppressive activity (38) . In
addition, it will also be important to investigate whether thesignal provided by a single cross-linked anti-CD2 mAb can
be replaced by LFA-3, the natural ligand for CD2 (12) .
There is evidence that theCD2andCD3/TCRactivation
pathways are functionally linked at least inT cells that ex-
press both molecules (27, 39) . Activation of ot/0+ T cells
viaCD2results in tyrosine phosphorylationoftheCD3/TCR
~chain (40), and suitable experimental conditions allow the
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